MARINUS PHARMACEUTICALS INC (MRNS) Stock Price, Forecast & Analysis
USA - NASDAQ:MRNS - US56854Q2003 - Common Stock
MRNS Key Statistics, Chart & Performance
The current stock price of MRNS is 0.55 USD. In the past month the price increased by 2.42%. In the past year, price decreased by -94.48%.
MRNS Latest News, Press Relases and Analysis
MRNS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.26 | 962.82B | ||
| JNJ | JOHNSON & JOHNSON | 19 | 475.01B | ||
| MRK | MERCK & CO. INC. | 10.59 | 232.99B | ||
| PFE | PFIZER INC | 7.88 | 143.42B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.16 | 95.65B | ||
| ZTS | ZOETIS INC | 18.99 | 53.37B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.54 | 22.85B | ||
| VTRS | VIATRIS INC | 4.6 | 12.50B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.98 | 10.48B | ||
| CORT | CORCEPT THERAPEUTICS INC | 86.25 | 8.00B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.99B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.20B |
Related stock screener links
About MRNS
Company Profile
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. The company is headquartered in Radnor, Pennsylvania and currently employs 165 full-time employees. The company went IPO on 2014-07-31. The firm is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The firm is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). The company is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
Company Info
MARINUS PHARMACEUTICALS INC
5 Radnor Corporate Center Suite 500, 100 Matsonford Rd
Radnor PENNSYLVANIA 19087 US
CEO: Scott Braunstein
Employees: 165
Phone: 14848014670
MARINUS PHARMACEUTICALS INC / MRNS FAQ
What does MRNS do?
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. The company is headquartered in Radnor, Pennsylvania and currently employs 165 full-time employees. The company went IPO on 2014-07-31. The firm is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The firm is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). The company is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
What is the current price of MRNS stock?
The current stock price of MRNS is 0.55 USD. The price increased by 0.09% in the last trading session.
Does MARINUS PHARMACEUTICALS INC pay dividends?
MRNS does not pay a dividend.
What is the ChartMill rating of MARINUS PHARMACEUTICALS INC stock?
MRNS has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does MARINUS PHARMACEUTICALS INC have?
MARINUS PHARMACEUTICALS INC (MRNS) currently has 165 employees.
What is the market capitalization of MRNS stock?
MARINUS PHARMACEUTICALS INC (MRNS) has a market capitalization of 30.37M USD. This makes MRNS a Nano Cap stock.
When does MARINUS PHARMACEUTICALS INC (MRNS) report earnings?
MARINUS PHARMACEUTICALS INC (MRNS) will report earnings on 2025-03-11, after the market close.
MRNS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MRNS. When comparing the yearly performance of all stocks, MRNS is a bad performer in the overall market: 72.37% of all stocks are doing better.
MRNS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MRNS. MRNS has a bad profitability rating. Also its financial health evaluation is rather negative.
MRNS Financial Highlights
Over the last trailing twelve months MRNS reported a non-GAAP Earnings per Share(EPS) of -2.44. The EPS increased by 7.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -220.81% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MRNS Forecast & Estimates
13 analysts have analysed MRNS and the average price target is 1.09 USD. This implies a price increase of 97.82% is expected in the next year compared to the current price of 0.55.
For the next year, analysts expect an EPS growth of 19.91% and a revenue growth 9.81% for MRNS